The IMF Tip Cards cover key myeloma treatment and care issues in a concise manner and are designed for you to carry with you as consistent references.
Gain a basic understanding of myeloma —what the disease is, its incidence, its symptoms, and how to get support.
Studies have demonstrated that lack of adherence to a treatment plan is a major reason for treatment failure
This laboratory-made monoclonal antibody targets a specific protein on the surface of myeloma cells.
Early diagnosis is key to achieving best outcomes for patients
This immunostimulatory monoclonal antibody is used in combination with lenalidomide + dexamethasone.
This histone deacetylase inhibitor is approved to treat myeloma in combination with bortezomib + dexamethasone.
These blood tests measure the concentration of free kappa and free lambda light chains (Freelite®) and the concentration of immunoglobulin pairs (Hevylite®).
This proteasome inhibitor is used in combination with dexamethasone, or with lenalidomide + dexamethasone.
Myeloma suppresses the immune system, reducing the number of normal antibodies and affecting all the cells that patrol for and attack abnormal cells.
The IMF’s Myeloma Matrix, designed to track drugs in development for myeloma, is now Myeloma Matrix 2.0: Smart Search, a clinical trial search tool developed by the IMF and Smart Patients.
This proteasome inhibitor is indicated for patients with myeloma who have received at least one prior therapy.
This immunomodulatory drug is indicated in combination with dexamethasone for myeloma patients who have received at least two prior therapies.
Protecting yourself and your medical information